Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870891 | 1.00 | ALDH1A1 (0.40) | ALDH1A1GAAMEN1KMT2AMAPT | |
| SCHEMBL10216957 | 0.80 | CTSS (0.43) | ALDH1A1MAPTLMNAMAPK1TSHR | |
| SCHEMBL5870886 | 0.79 | KCNQ2 (0.48) | ALDH1A1GAAMEN1KMT2AMAPT | |
| SCHEMBL5674426 | 0.78 | CYP3A4 (0.47) | MEN1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL12480409 | 0.78 | NPSR1 (0.41) | ALDH1A1MAPTLMNAMAPK1TSHR | |
| SCHEMBL10217257 | 0.78 | NPSR1 (0.41) | ALDH1A1MAPTLMNAMAPK1TSHR | |
| SCHEMBL30483968 | 0.78 | NPSR1 (0.41) | ALDH1A1MAPTLMNAMAPK1TSHR | |
| SCHEMBL30146902 | 0.78 | NPSR1 (0.41) | ALDH1A1MAPTLMNAMAPK1TSHR | |
| SCHEMBL25445027 | 0.75 | CTSS (0.47) | ALDH1A1TSHRPOLBSMN1; SMN2NPSR1 | |
| SCHEMBL29770841 | 0.75 | CTSS (0.47) | ALDH1A1TSHRPOLBSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144881-B2 | Arylcyclopropylcarboxylic amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1581510-A4 | 1-ARYL-2-HYDROXYETHYL AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL MYERS SQUIBB CO (US) | 2006-08-30 | — | — | EP | disclosed |
| US-7045551-B2 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| EP-1581510-A2 | 1-ARYL-2-HYDROXYETHYL AMIDES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040122007-A1 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004047743-A2 | 1-ARYL-2-HYDROXYETHYL AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122007-A1 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | KCNQ3, KCNQ2, KCNQ4 | ALDH1A1 597/4885GAA 3312/4885MEN1 1207/4885 |
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | KCNQ2, KCNQ5, KCNJ2 | ALDH1A1 954/4885GAA 2924/4885MEN1 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.